Return to the past: the case for antibody-based therapies in infectious diseases.
about
Passive immunity in prevention and treatment of infectious diseasesDelayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaquesA human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infectionWanted, dead or alive: New viral vaccinesMonoclonal antibody-based therapies for microbial diseasesEbolavirus glycoprotein structure and mechanism of entryProtective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis.Therapeutic antibodies: current state and future trends--is a paradigm change coming soon?Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening.Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infectionsIdentification of ABC transporters in vancomycin-resistant Enterococcus faecium as potential targets for antibody therapy.Neutralizing antibody fails to impact the course of Ebola virus infection in monkeysUsing monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases.Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.A non-chromatographic method for the purification of a bivalently active monoclonal IgG antibody from biological fluidsEffective combination therapy for invasive pneumococcal pneumonia with ampicillin and intravenous immunoglobulins in a mouse model.Monoclonal antibody-mediated modulation of the humoral immune response against mucosally applied Streptococcus mutans.Botulinum neurotoxins and botulism: a novel therapeutic approach.Engineering venom's toxin-neutralizing antibody fragments and its therapeutic potential.Structure-function relationships for human antibodies to pneumococcal capsular polysaccharide from transgenic mice with human immunoglobulin Loci.Mucosal immunity and viral infections.Adjunctive immune therapy for fungal infections.Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.Passive antibody administration (immediate immunity) as a specific defense against biological weapons.Rebmab200, a humanized monoclonal antibody targeting the sodium phosphate transporter NaPi2b displays strong immune mediated cytotoxicity against cancer: a novel reagent for targeted antibody therapy of cancerPost-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy.The Ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases.Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.What is infectiveness and how is it involved in infection and immunity?Genetically recombinant antibodies: new therapeutics against candidiasis.Passive antibody therapy for infectious diseases.The birth pangs of monoclonal antibody therapeutics: the failure and legacy of CentoxinAnti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs.The versatile roles of antibodies in Borrelia infections.Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant.The potential of antibody-mediated immunity in the defence against biological weapons.Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses.Development of recombinant human polyclonal antibodies for the treatment of complex human diseases.Manufacture of recombinant polyclonal antibodies.
P2860
Q24550699-B078769A-99FA-4516-9413-A13836234DB8Q24612811-ACF04264-F5F7-4B90-9C97-84E3EDBE9E33Q24672825-D05D25D5-AE57-4C48-89D4-E3AF617B7B5BQ27489979-B8820AFF-CBC7-433D-BABA-36002EC64584Q27490830-82949896-2575-4439-992F-9987DFDCB371Q27490991-78596851-AFE5-4C15-9302-14B805881970Q28384322-221D261A-9C0B-45C7-AB4E-14596C1AA445Q28728956-9AF1867A-B514-46BC-B80F-C43F733B01EFQ30423024-4EE752AE-303D-4ADF-9A17-AD560AD2AF2AQ30431941-C4A09B59-D0FC-497A-87CE-96C6A0159218Q30872027-7B2ADA88-3A01-4F84-BBFE-725421EC6051Q31096142-20A9DB82-34E1-4F63-92A3-322806FFC65DQ33269796-943760AB-81A6-4878-B4D6-BD94F91819D3Q33542433-3EA35FF7-86EB-47E9-86FD-77407EE5F85CQ33647300-6928E921-8F88-406F-B544-D849C385CC28Q33752932-32DDE21D-A505-4D36-90E2-BA333C66431CQ33981259-BB63C44A-840C-4852-9DCC-1C3896D96F58Q34003768-A98EA4BD-60F2-4556-B13A-5F963F4E6BABQ34070659-5F52D1E9-3D17-46B6-BFCA-EE970810E29DQ34101828-3E958935-B993-4A5A-BD86-E34330D8F229Q34130657-6991B021-610E-4481-B1A5-BA2AE5E04F36Q34259769-A0117EC0-B103-44BD-A084-AD049E8993FAQ34350401-E1ED5211-4FF6-496B-9F04-1ECF71FCDF34Q34648342-6B9ABC07-4292-4638-B5B8-3CA406324ED8Q34762095-E7983DD2-B017-4E9C-94D0-3E1C4F26062BQ34922631-8ACE7E9C-53A5-4FCC-B0FC-6E29688B2A91Q35107644-D0269A08-C886-41F9-AF07-FA40AE46A18DQ35532972-F18331A1-586F-4642-A59A-B1A26F71D160Q35544888-721DEF53-4202-476F-A31D-C3E8B6F2D21EQ35607564-1B900E72-E2BE-4235-9B61-4381D7C38734Q35681522-A75DBFA2-F12D-4CDF-8E53-19A8B3FF0843Q35889582-486D955D-A4B5-46A4-B725-314F91B30217Q35969881-9663AB15-902E-4B07-AE5C-376B07183ED4Q36046633-B37461AA-F8E0-4D9F-86C0-3BAA0D8FE11DQ36111888-BE42067D-B2D4-4E8D-A04E-2C5753C21E59Q36183762-9EE02B9A-8568-4AB4-8B80-56C21F022829Q36273411-EDEFC4D5-D145-4B1D-9743-F03EB4E549E9Q36379337-25CA1265-AD43-4EC5-B1F1-6B77432378D4Q36569741-0EF045F8-42AE-4552-B325-E70D6C6F1AEEQ36740161-B7CDEEB3-3E71-4E23-B171-96B09DEBF4D9
P2860
Return to the past: the case for antibody-based therapies in infectious diseases.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Return to the past: the case for antibody-based therapies in infectious diseases.
@en
type
label
Return to the past: the case for antibody-based therapies in infectious diseases.
@en
prefLabel
Return to the past: the case for antibody-based therapies in infectious diseases.
@en
P356
P1476
Return to the past: the case for antibody-based therapies in infectious diseases.
@en
P2093
Casadevall A
Scharff MD
P304
P356
10.1093/CLINIDS/21.1.150
P407
P577
1995-07-01T00:00:00Z